Literature DB >> 3814464

Conclusiveness of rechallenge in the interpretation of adverse drug reactions.

M Girard.   

Abstract

We here consider the extent to which the presumed correlation between an adverse event and the administration of a particular drug can be reinforced by rechallenge. At first question of terminology is: what is a rechallenge? Rechallenge is often accepted too readily as proof of a causal relationship and clinical examples give illustrations of common misinterpretations. Definitions are proposed to characterize: the outcome of rechallenge; the conditions under which rechallenge is performed. In discussing causality, a sharp distinction is drawn between the outcome per se and the establishment of a causal relationship. Finally, the simple concepts proposed here should permit to establish a typology of rechallenge and to assess, by further experimental or retrospective research, the conclusiveness of rechallenge in interpreting adverse drug reactions.

Mesh:

Substances:

Year:  1987        PMID: 3814464      PMCID: PMC1386142          DOI: 10.1111/j.1365-2125.1987.tb03011.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  10 in total

1.  An algorithm for the operational assessment of adverse drug reactions. I. Background, description, and instructions for use.

Authors:  M S Kramer; J M Leventhal; T A Hutchinson; A R Feinstein
Journal:  JAMA       Date:  1979-08-17       Impact factor: 56.272

2.  Exfoliative dermatitis and practolol.

Authors:  M G Rowland; C J Stevenson
Journal:  Lancet       Date:  1972-05-20       Impact factor: 79.321

3.  Cutaneous and ocular reactions to practolol.

Authors:  R H Felix; F A Ive; M G Dahl
Journal:  Br Med J       Date:  1974-11-09

4.  Clinical biostatistics. II. Statistics versus science in design of experiments.

Authors:  A R Feinstein
Journal:  Clin Pharmacol Ther       Date:  1970 Mar-Apr       Impact factor: 6.875

5.  Adverse nondrug reactions.

Authors:  M M Reidenberg; D T Lowenthal
Journal:  N Engl J Med       Date:  1968-09-26       Impact factor: 91.245

6.  Deliberate drug rechallenge.

Authors:  M Stephens
Journal:  Hum Toxicol       Date:  1983-10

7.  [Is rechallenge necessary for complete imputability? Comparative value of 7 methods of determining imputability].

Authors:  E Loupi; A C Ponchon; J J Ventre; J Descotes; J C Evreux
Journal:  Therapie       Date:  1984 Sep-Oct       Impact factor: 2.070

Review 8.  Clinical prediction rules. Applications and methodological standards.

Authors:  J H Wasson; H C Sox; R K Neff; L Goldman
Journal:  N Engl J Med       Date:  1985-09-26       Impact factor: 91.245

9.  Aggravation of psoriasis and occurrence of psoriasiform cutaneous eruptions induced by practolol (Eraldin).

Authors:  J Sondergaard; S Wadskov; H A Jensen; H I Mikkelsen
Journal:  Acta Derm Venereol       Date:  1976       Impact factor: 4.437

10.  Cutaneous reactions to practolol. Clinical and histopathological study.

Authors:  K Kauppinen; K M Niemi; O P Salo
Journal:  Ann Clin Res       Date:  1976-08
  10 in total
  16 in total

1.  Identifying drugs that cause acute thrombocytopenia: an analysis using 3 distinct methods.

Authors:  Jessica A Reese; Xiaoning Li; Manfred Hauben; Richard H Aster; Daniel W Bougie; Brian R Curtis; James N George; Sara K Vesely
Journal:  Blood       Date:  2010-06-08       Impact factor: 22.113

2.  Evidence of Misclassification of Drug-Event Associations Classified as Gold Standard 'Negative Controls' by the Observational Medical Outcomes Partnership (OMOP).

Authors:  Manfred Hauben; Jeffrey K Aronson; Robin E Ferner
Journal:  Drug Saf       Date:  2016-05       Impact factor: 5.606

3.  Bronchial hyperreactivity in patients who cough after receiving angiotensin converting enzyme inhibitors.

Authors:  C E Bucknall; J B Neilly; R Carter; R D Stevenson; P F Semple
Journal:  Br Med J (Clin Res Ed)       Date:  1988-01-09

Review 4.  Defining 'signal' and its subtypes in pharmacovigilance based on a systematic review of previous definitions.

Authors:  Manfred Hauben; Jeffrey K Aronson
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

5.  Technical expertise as an ethical form: towards an ethics of distance.

Authors:  M Girard
Journal:  J Med Ethics       Date:  1988-03       Impact factor: 2.903

6.  Intentional rechallenge: does the benefit outweigh the risk?

Authors:  Vid Stanulović; Mauro Venegoni; Brian Edwards
Journal:  Drug Saf       Date:  2013-03       Impact factor: 5.606

7.  Revisiting the reported signal of acute pancreatitis with rasburicase: an object lesson in pharmacovigilance.

Authors:  Manfred Hauben; Eric Y Hung
Journal:  Ther Adv Drug Saf       Date:  2016-05-23

Review 8.  The epidemiology of serious adverse drug reactions among the elderly.

Authors:  P A Atkin; P C Veitch; E M Veitch; S J Ogle
Journal:  Drugs Aging       Date:  1999-02       Impact factor: 3.923

9.  [Clinical practise guideline of the special interest group in allergy of the ÖGDV - Drug provocation testing in the diagnosis of cutaneous drug reactions].

Authors:  Birger Kränke; Werner Aberer; Cornelia Egger; Thomas Hawranek; Norbert Reider; Beatrix Volc-Platzer; Stefan Wöhrl
Journal:  Wien Klin Wochenschr       Date:  2011-09-02       Impact factor: 1.704

10.  Evaluation of the safety of enalapril in the treatment of heart failure in the very old.

Authors:  C J O'Neill; S G Bowes; C M Sullens; J P Royston; W B Hunt; M J Denham; R J Dobbs; S M Dobbs
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.